DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Breast Cancer
  4. Research Highlights/News
  5. FY22 Breast Cancer Research Program

Breast Cancer

NEWS RELEASE

Released: October 7, 2022

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Breast Cancer Research Program (BCRP)
Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)

The FY22 Defense Appropriations Act provides funding for the BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service Members, Veterans, and the general public. The managing agent for the anticipated funding opportunity is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The BCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunity. This pre-announcement should not be construed as an obligation by the government. The FY22 BCRP funding opportunity announcement for the following award mechanism will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcement is released.

Applications submitted to the FY22 BCRP must address one or more of the following overarching challenges:

  • Prevent breast cancer (primary prevention)
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers
  • Conquer the problems of overdiagnosis and overtreatment
  • Identify what drives breast cancer growth; determine how to stop it
  • Identify why some breast cancers become metastatic
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
  • Eliminate the mortality associated with metastatic breast cancer

Award Mechanism Eligibility Key Mechanism Elements Funding
Clinical Research Extension Award

NEW for FY22

 Investigators at all academic levels (or equivalent)
  • Supports research that extends the data collection, follow-up, and analysis of breast cancer clinical research studies.
  • The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis.
  • Although not all-inclusive, research proposed under this mechanism may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial.
  • Principal Investigators (PIs) are required to include two or more breast cancer advocates on their research team.
  • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to partner on a single application.
  • Submission of a Letter of Intent is required prior to full application submission.
  • Clinical trials are not allowed.
    •
  • Maximum funding of $5 million (M) for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years

      Partnering PI Option:

  • Maximum funding of $6M for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years

A pre-application is required and must be submitted through the Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-ncdmrp.mbx.cdmrp-public-affairs@health.mil


Last updated Friday, October 7, 2022